Is STAAR Surgical Company (NASDAQ:STAA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating STAAR Surgical Company at current levels.
China demand is normalizing off a brutal base, and the ICL replacement-for-LASIK story is just getting started in the West.
Where STAA is headed
STAAR is the only company on the planet selling a removable, non-tissue-destroying alternative to LASIK at scale, and the next 24 months are about proving that thesis outside of Asia. The Implantable Collamer Lens (ICL) has spent a decade as 'the thing Chinese ophthalmologists love.' That China concentration almost killed the equity in 2024-2025 when inventory destocking and a consumer slowdown collapsed revenue and torched the multiple from $120 to the mid-teens. The trailing 119% revenue growth print is base-effect noise off that trough. What matters is the shape of the recovery, and the shape is starting to look like a different company.
Read the full Compass Direction on STAA
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $32.47).
See the full STAA analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is STAAR Surgical Company (NASDAQ:STAA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating STAAR Surgical Company at current levels. China demand is normalizing off a brutal base, and the ICL replacement-for-LASIK story is just getting started in the West.
What is STAA's Compass Score?
STAAR Surgical Company scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for STAA?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the STAA page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.